Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CSPI alleges VitaminWater claims false

This article was originally published in The Tan Sheet

Executive Summary

One month after FDA sent a letter to Coca-Cola warning that the beverage firm misbranded its Diet Coke Plus, the Atlanta-based firm's VitaminWater is the target of a proposed class action lawsuit. This time, the Center for Science in the Public Interest files a suit in the U.S. District Court in the Northern District of California alleging the company falsely advertises its VitaminWateras a healthy alternative to soda. Each bottle of VitaminWater has 33 grams of sugar and makes claims that "go far beyond even the loose, so-called 'structure/function claims' allowed by" FDA, CSPI says in a Jan. 15 release. Coca-Cola could not be reached for comment. FDA has warned that Diet Coke Plus does not contain enough nutrients for a "plus" claim (1"The Tan Sheet" Jan. 5, 2009, p. 9)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel